"New cytokinin derivatives for agriculture and medicine" . "Dole\u017Eal, Karel" . . "Lenobel, Ren\u00E9" . . "Binarov\u00E1, Pavla" . "New cytokinin derivatives for agriculture and medicine"@en . . "8"^^ . . . "New cytokinin derivatives for agriculture and medicine"@en . "6"^^ . . . . "76" . "Kry\u0161tof, Vladim\u00EDr" . . . "New series of cytokinins derived from 6-benzylaminopurine have been developed for agricultural and biotechnological applications. These compounds exhibit very high biological activities in different cytokinin bioassays. The methoxy and fluoro derivatives exhibited 2-10 times higher activity then trans-zeatin and expressed very positive antisenescent and morphogenetic properties in different in vitro cultures. Among aromatic cytokinin derivatives, we have discovered a compound, 2-(2-hydroxyethylamino)-6-benzylamino-9-methylpurine, named %22olomoucine%22 (OC), which specifically inhibits some cyclin-dependent kinases (CDKs) at micromolar concentration. The design and inhibitory activity of OC was further improved by modifications at positions 2, 6, and 9. This has led to development of specific CDK inhibitors like roscovitine, olomoucine II and purvalanol A, which display an enhanced inhibitory activity toward CDK1, a higher selectivity for some CDKs, an increased antimitotic activity at the G1/S and G2/M" . . "576056" . . "15310" . "Canberra" . . . . "New series of cytokinins derived from 6-benzylaminopurine have been developed for agricultural and biotechnological applications. These compounds exhibit very high biological activities in different cytokinin bioassays. The methoxy and fluoro derivatives exhibited 2-10 times higher activity then trans-zeatin and expressed very positive antisenescent and morphogenetic properties in different in vitro cultures. Among aromatic cytokinin derivatives, we have discovered a compound, 2-(2-hydroxyethylamino)-6-benzylamino-9-methylpurine, named %22olomoucine%22 (OC), which specifically inhibits some cyclin-dependent kinases (CDKs) at micromolar concentration. The design and inhibitory activity of OC was further improved by modifications at positions 2, 6, and 9. This has led to development of specific CDK inhibitors like roscovitine, olomoucine II and purvalanol A, which display an enhanced inhibitory activity toward CDK1, a higher selectivity for some CDKs, an increased antimitotic activity at the G1/S and G2/M"@en . "Nov\u00E9 deriv\u00E1ty cytokinin\u016F pro zem\u011Bd\u011Blstv\u00ED a medic\u00EDnu"@cs . "18th IPGSA conference, Conference Handbook" . . . "Australian National University" . . "Havl\u00ED\u010Dek, Libor" . "RIV/61989592:15310/04:00002278!RIV/2005/GA0/153105/N" . "Popa, Igor" . "Strnad, Miroslav" . "[FAB0F7A1668D]" . . "Nov\u00E9 deriv\u00E1ty cytokinin\u016F pro zem\u011Bd\u011Blstv\u00ED a medic\u00EDnu"@cs . . . . "P(GA522/01/0275), Z(MSM 153100008)" . "144"^^ . "RIV/61989592:15310/04:00002278" . "Cytokinin;6-benzylaminopurine;olomoucine;bohemine;roscovitine;antitumour effects"@en . "Zatloukal, Marek" . "New cytokinin derivatives for agriculture and medicine" . "Jsou pops\u00E1ny nov\u00E9 deriv\u00E1ty cytokinin\u016F pro zem\u011Bd\u011Blstv\u00ED a medic\u00EDnu."@cs . . . .